SynthesisFrontiers in oncology2024

The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials.

Zhigang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.